FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
For Immediate Release: March 25, 2026 The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II). “Today is a milestone day for children and …